1,2-Dihydro-6-methoxycarbazol-3(4H)-on | 25473-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,2-Dihydro-6-methoxycarbazol-3(4H)-on
• 英文别名: 6-methoxy-1,2,4,9-tetrahydro-carbazol-3-one；6-methoxy-1,2,4,9-tetrahydro-3H-carbazol-3-one；6-methoxy-2,3,4,9-tetrahydro-1H-carbazol-3-one；6-methoxy-1,2,4,9-tetrahydrocarbazol-3-one
• CAS: 25473-71-6
• 化学式: C₁₃H₁₃NO₂
• mdl: MFCD21218685
• 分子量: 215.252
• InChiKey: CISGDMAISVQRCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,2-Dihydro-6-methoxycarbazol-3(4H)-on 在 oxonium 、 sodium hydride 、 sodium amide 、 叔丁醇 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Design of new anticancer drugs. II. Easy arynic access to benzocyclobutacarbazoles, a new family of antitumor agents

  摘要：

  Tetrahydrobenzocyclobutacarbazoles with antitumoral properties were obtained either by arynic condensation of aryl halides with 3-carbazolone enolates or arynic cyclisation of halogenated arylimine enolates of 2-biphenylenones in the presence of the complex base NaNH2-tBuONa. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02186-8
• 作为产物：
  描述：

  3-ethylene acetal-1,2,4,9-tetrahydro-6-methoxy-3H-carbazol-3-one 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以68%的产率得到1,2-Dihydro-6-methoxycarbazol-3(4H)-on
  参考文献：
  名称：

  [EN] TRICYCLIC CYTOPROTECTIVE COMPOUNDS
  [FR] COMPOSES CYTOPROTECTEURS TRICYCLIQUES

  摘要：

  公开号：

  WO2006082409A3

文献信息

• Synthesis and antiproliferative activity of Benzocyclobutacarbazol derivatives. A new class of potential antitumor agents
  作者：S Graf-Christophe、C Kuehm-Caubère、P Renard、B Pfeiffer、A Pierré、S Léonce、P Caubère

  DOI：10.1016/s0960-894x(00)00532-1

  日期：2000.12

  Several benzocyclobutacarbazol derivatives were synthesized and evaluated for their potential cytotoxic properties. A number of these compounds exhibited significant antiproliferative activity with concomitant interaction with the cell cycle and represent a new class of potential anticancer agents.

  合成了几种苯并环丁卡巴唑衍生物，并评估了其潜在的细胞毒性。这些化合物中的许多显示出显着的抗增殖活性以及与细胞周期的相互作用，并且代表了一类新的潜在抗癌剂。
• TRICYCLIC CYTOPROTECTIVE COMPOUNDS
  申请人：Wulfert Ernst

  公开号：US20090259043A1

  公开（公告）日：2009-10-15

  Compounds of formula (I): [in which: X is a group of formula >CR 1 R 2 or >SO 2 ; Y is a group of formula >NH or >CR 1 R 2 ; Z is a group of formula >C═O or >CH 2 or a direct bond; R 1 is hydrogen and R 2 is hydrogen, carboxy or hydroxy; or R 1 and R 2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R 3 is hydrogen or lower alkyl; R 4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R 5 is hydrogen, lower alkyl or halogen; R 6 is hydrogen, lower alkoxy or carboxy; R 7 and R 8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

  式(I)的化合物：[其中：X是公式>CR1R2或>SO2的基团；Y是公式>NH或>CR1R2的基团；Z是公式>C═O或>CH2或直接键的基团；R1是氢原子，R2是氢原子，羧基或羟基；或R1和R2一起代表氧代基、甲亚基二氧基基团或羟基亚胺基团；R3是氢原子或较低的烷基；R4代表两个氢原子或氧代基或羟基亚胺基团；R5是氢原子、较低的烷基或卤素；R6是氢原子、较低的烷氧基或羧基；R7和R8均为氢原子、较低的烷基或卤素；以及其药学上可接受的盐和酯，可用于治疗或预防急性或慢性神经退行性疾病或病症，如阿尔茨海默病、帕金森病、亨廷顿舞蹈病、多发性硬化症或急性缺血事件的后遗症，如心脏病发作、中风或头部损伤，并用于保护外周器官组织免受缺血性损伤。
• Tricyclic Cytoprotective Compounds
  申请人：Wulfert Ernst

  公开号：US20080146644A1

  公开（公告）日：2008-06-19

  Compounds of formula (I): [in which: X is a group of formula >CR 1 R 2 or >SO 2 ; Y is a group of formula >NH or >CR 1 R 2 ; Z is a group of formula >C═O or >CH 2 or a direct bond; R 1 is hydrogen and R 2 is hydrogen, carboxy or hydroxy; or R 1 and R 2 together represent an oxo group, a methylenedioxy group or a hydroxyimino group; R 3 is hydrogen or lower alkyl; R 4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R 5 is hydrogen, lower alkyl or halogen; R 6 is hydrogen, lower alkoxy or carboxy; R 7 and R 8 are each hydrogen, lower alkyl or halogen; and pharmaceutically acceptable salts and esters thereof can be used for the treatment or prophylaxis of acute or chronic neurodegenerative diseases or conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Chorea, Multiple Sclerosis or the sequelae to acute ischaemic events such as heart attack, stroke or head injury and for protection against ischaemic damage to tissues of peripheral organs.

  化合物的公式 (I)：[其中：X 是公式 >CR1R2 或 >SO2 的基团；Y 是公式 >NH 或 >CR1R2 的基团；Z 是公式 >C═O 或 >CH2 或直接键；R1 是氢原子，R2 是氢原子，羧基或羟基；或者 R1 和 R2 一起表示一个氧代基团、一个甲二氧基基团或一个羟肟基团；R3 是氢原子或低碳基；R4 表示两个氢原子，或一个氧代基团或羟肟基团；R5 是氢原子、低碳基或卤素；R6 是氢原子、低烷氧基或羧基；R7 和 R8 分别是氢原子、低碳基或卤素；以及其药学上可接受的盐和酯，可用于治疗或预防急性或慢性神经退行性疾病或病症，如阿尔茨海默病、帕金森病、亨廷顿舞蹈病、多发性硬化症或急性缺血事件的后遗症，如心脏病发作、中风或头部损伤，并保护外围器官组织免受缺血损伤。
• MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS
  申请人：Wülfert Ernst

  公开号：US20100137270A1

  公开（公告）日：2010-06-03

  A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2.
• Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways
  申请人：WULFERT ERNST

  公开号：US20130023504A1

  公开（公告）日：2013-01-24

  A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2.